van der Vijgh WJ - Search Results

1

Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice.

Treskes M, Boven E, van de Loosdrecht AA, Wijffels JF, Cloos J, Peters GJ, Pinedo HM, van der Vijgh WJ. Treskes M, et al. Among authors: van der vijgh wj, van de loosdrecht aa. Eur J Cancer. 1994;30A(2):183-7. doi: 10.1016/0959-8049(94)90084-1. Eur J Cancer. 1994. PMID: 8155393

2

Protection by WR-2721 of the toxicity induced by the combination of cisplatin and 5-fluorouracil.

Peters GJ, van der Wilt CL, Gyergyay F, van Laar JA, Treskes M, van der Vijgh WJ, Pinedo HM. Peters GJ, et al. Among authors: van der vijgh wj, van der wilt cl, van laar ja. Int J Radiat Oncol Biol Phys. 1992;22(4):785-9. doi: 10.1016/0360-3016(92)90524-l. Int J Radiat Oncol Biol Phys. 1992. PMID: 1312075

3

Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse.

Treskes M, Boven E, Holwerda U, Pinedo HM, van der Vijgh WJ. Treskes M, et al. Among authors: van der vijgh wj. Cancer Res. 1992 Apr 15;52(8):2257-60. Cancer Res. 1992. PMID: 1313740

4

The reversal of cisplatin-protein interactions by the modulating agent WR2721 and its metabolites WR1065 and WR33278.

Treskes M, Holwerda U, Nijtmans LG, Pinedo HM, van der Vijgh WJ. Treskes M, et al. Among authors: van der vijgh wj. Cancer Chemother Pharmacol. 1992;29(6):467-70. doi: 10.1007/BF00684849. Cancer Chemother Pharmacol. 1992. PMID: 1314713

5

Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil.

van Laar JA, van der Wilt CL, Treskes M, van der Vijgh WJ, Peters GJ. van Laar JA, et al. Among authors: van der vijgh wj, van der wilt cl. Cancer Chemother Pharmacol. 1992;31(2):97-102. doi: 10.1007/BF00685094. Cancer Chemother Pharmacol. 1992. PMID: 1333372

6

Cytostatic activity of cisplatin in the presence of WR2721 and its thiol metabolite WR1065 in OVCAR-3 human ovarian cancer cells as compared to V79 fibroblasts.

Treskes M, Nijtmans L, Fichtinger-Schepman AM, van der Vijgh WJ. Treskes M, et al. Among authors: van der vijgh wj. Anticancer Res. 1992 Nov-Dec;12(6B):2261-5. Anticancer Res. 1992. PMID: 1338281

7

The chemical reactivity of the modulating agent WR2721 (ethiofos) and its main metabolites with the antitumor agents cisplatin and carboplatin.

Treskes M, Holwerda U, Klein I, Pinedo HM, van der Vijgh WJ. Treskes M, et al. Among authors: van der vijgh wj. Biochem Pharmacol. 1991 Nov 6;42(11):2125-30. doi: 10.1016/0006-2952(91)90347-8. Biochem Pharmacol. 1991. PMID: 1659819

8

Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (WR-2721): preclinical aspects.

Peters GJ, van der Vijgh WJ. Peters GJ, et al. Among authors: van der vijgh wj. Eur J Cancer. 1995;31A Suppl 1:S1-7. doi: 10.1016/0959-8049(95)00145-9. Eur J Cancer. 1995. PMID: 7577093 Review.

9

Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (Ethyol): preclinical aspects.

van der Vijgh WJ, Peters GJ. van der Vijgh WJ, et al. Semin Oncol. 1994 Oct;21(5 Suppl 11):2-7. Semin Oncol. 1994. PMID: 7973774 Review.

10

WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.

Treskes M, van der Vijgh WJ. Treskes M, et al. Among authors: van der vijgh wj. Cancer Chemother Pharmacol. 1993;33(2):93-106. doi: 10.1007/BF00685326. Cancer Chemother Pharmacol. 1993. PMID: 8261581 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

217 results

Search Page

Filters